首页 | 本学科首页   官方微博 | 高级检索  
     


DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin
Authors:Yu Pei MD  Bue R. Agner MD  Bin Luo MD  Xiaolin Dong MD  Dongmei Li MD  Jun Liu MD  Lei Liu MD  Ming Liu MD  Yibing Lu MD  Tomoyuki Nishida MSc  Xiangjin Xu MD  Yiming Mu MD
Affiliation:1. Department of Endocrinology, Chinese People's Liberation Army General Hospital, Beijing, China;2. Bispebjerg Hospital, Copenhagen, Denmark;3. Novo Nordisk China Pharmaceuticals, Beijing, China;4. Department of Endocrinology, Jinan Central Hospital, Shandong University, Jinan, China;5. Department of Endocrinology, Inner Mongolia People's Hospital, Hohhot, China;6. Department of Endocrinology, Fifth People's Hospital of Shanghai, Shanghai, China;7. Novo Nordisk A/S, Søborg, Denmark;8. Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China;9. Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China;10. Novo Nordisk Pharma Ltd, Tokyo, Japan;11. Department of Endocrinology, Fuzhou General Hospital, Fuzhou, China
Abstract:
Keywords:Chinese  insulin  insulin degludec/liraglutide  type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号